possible role of soluble fibrin monomer complex after gastroenterological surgery

Table 2 The relationship between the D-dimer level on POD 7 and the clinical characteristics of patients who did not receive anticoagulant therapy

Clinical risk factors for VTE	D-dimer (POD 7)		Univariate	Multivariate
	Low(< 6.45)	High(≥6.45)	P value	OR	95%CI	P value
Age
< 75	37	26	< 0.01	2.48	0.70-9.21	0.15
≥ 75	7	18
Sex
Male	20	21	0.83
Female	24	23
Performance status
0-2	43	43	1.00
3-4	1	1
Operative time (min)
< 321	32	19	< 0.01	2.09	0.64-6.92	0.21
≥ 321	12	25
Bleeding volume (mL)
< 113	35	28	0.09
≥ 113	9	16
Laparoscopic surgery
No	11	16	0.24
Yes	33	28
Malignancy
Absence	2	3	0.64
Presence	42	41
Metastatic disease
Absence	38	39	0.74
Presence	6	5
Diabetes mellitus
Absence	39	39	1.00
Presence	5	5
Hormone therapy
Absence	43	43	1.00
Presence	1	1
CV catheter
Absence	42	43	0.55
Presence	2	1
Preoperative infection
Absence	42	41	0.64
Presence	2	3
Antiplatelet therapy
Absence	41	40	0.69
Presence	3	4
Pelvic surgery
Absence	41	41	1.00
Presence	3	3
Caprini score
< 7	24	15	0.05
≥ 7	20	29
Fibrin-related markers
D-dimer (μg/mL) < 0.6	17	12	0.11
Preoperative ≥ 0.6	13	21
D-dimer (μg/mL) < 3.8	33	11	< 0.01	2.88	0.56-14.82	0.19
POD1 ≥ 3.8	11	33
FDP (μg/mL) < 10.1	38	18	< 0.01	1.42	0.25-7.65	0.68
POD1 ≥ 10.1	6	26
TAT (ng/mL) POD1
< 8.3	34	12	< 0.01	1.83	0.44-7.27	0.39
≥ 8.3	10	32
SFMC (μg/mL) < 3.8	39	16	< 0.01	4.31	1.10-18.30	0.03
POD1 ≥ 3.8	5	28

VTE: Venous thromboembolism; CV: Central vein; FDP: Fibrin degradation products; TAT: Thrombin antithrombin complex; SFMC: Soluble fibrin monomer complex; POD: Postoperative day.